Navigation Links
Vioxx's Heart Risk Lingered Long After Use Ended
Date:10/13/2008

ed that the risk for heart attack and stroke continued even after Vioxx was stopped.

"What this does is help further demonstrate not only the risk of Vioxx, but the temporal duration," Topol said. "Now, we have compelling data that the risk extends a year after stopping the drug," he said.

Topol, who was one of the first to sound the alarm about Vioxx, is not sure that this is a class effect of all cox-2 inhibitors, however.

"There was always a signal that it [the risk] was worse for Vioxx that other cox-2 inhibitors. Whether or not other drugs like Celebrex shared that isn't known. That has not been demonstrated in studies of Celebrex. But you have to be suspicious, particularly since high doses of Celebrex have heart attack and stroke risk. But there's never been a study to show that it's a long-lasting liability," he said.

More information

For more about pain relievers, visit the U.S. National Library of Medicine.



SOURCES: Robert Bresalier, M.D., professor, medicine, M.D. Anderson Cancer Center, University of Texas, Houston; Eric J. Topol, M.D., director, Scripps Translational Science Institute, Chief Academic Officer, Scripps Health, La Jolla, Calif; Oct. 13, 2008, online edition, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Hospital-based smoking cessation program after heart attack adds to success
2. Little-Known Fat Can Be a Heartbreaker
3. Blood Cell Genes May Signal Heart Disease
4. Touchstone Health Partners with the American Heart Association and American Stroke Association to Fight Cardiovascular Disease Among Seniors
5. Florida study finds barriers to angioplasty for life-threatening heart attacks
6. Northwestern Memorial trials implantable device to manage congestive heart failure symptoms
7. "PEACE of Heart" Campaign Comes to Metro Washington to Help Fight Heart Disease Epidemic among Minorities : Hallmark of Campaign's Health Screening Events Is Personalized Follow-Up
8. MultiVu Video Feed: NEW RESEARCH PUBLISHED IN THE AMERICAN JOURNAL OF CLINICAL NUTRITION FINDS PISTACHIOS IMPROVE RISK FACTORS FOR HEART DISEASE
9. American Heart Association Announces Start! Fit-Friendly Companies
10. American Heart Association Calls on Presidential Candidates to Adopt the Organizations New Principles on Healthcare Reform
11. Heart CT Scan Helps Find Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vioxx's Heart Risk Lingered Long After Use Ended
Vioxx's Heart Risk Lingered Long After Use Ended
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3Cosmetic Bootcamp University New York Deemed A Huge Success 59289 1Noninvasive Medical Technologies Supports 824 Mile Tim Davis Special Tactics Memorial March 59286 1Noninvasive Medical Technologies Supports 824 Mile Tim Davis Special Tactics Memorial March 59286 2Noninvasive Medical Technologies Supports 824 Mile Tim Davis Special Tactics Memorial March 59286 3Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 1Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 2Researchers Present a Novel Automated Efficient Environmental Disinfection Technology that Significantly Reduces C difficile VRE and MRSA Contamin 14436 3